Ionis Pharma (IONS) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ionis Pharmaceuticals (IONS) PT Lifted to $46 at Piper Jaffray
August 10, 2016 7:27 AM EDTPiper Jaffray analyst Joshua Schimmer reiterated an Overweight rating and raised his price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $46.00 (from $36.00) following Q2 earnings and an update on its antisense pipeline.
Schimmer commented, "The company provided some color on nusinersen for the... More
